Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction With High Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma.

Next Previous
Trial Profile

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction With High Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms Mel-Vel

Most Recent Events

  • 07 Jun 2016 Results of an updated analysis of 2 studies (NCT00784823; n=29 and NCT01242267; n=32) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
  • 17 Jul 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 17 Jul 2013 Planned end date changed from 1 Dec 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top